| 中文名称： | PF-AKT400 | 中文别名： | PF-AKT400 |
|---|---|---|---|
| 英文名称： | PF-AKT400 | CAS： | 1004990-28-6 |
| 产品分类： | 小分子化合物 | 纯度： | ≥98% |
| 产品编号 | 品牌 | 纯度 | 规格 | 库存 | 价格 |
|---|---|---|---|---|---|
| IP5120 | 索莱宝 | ≥98% | 1mg | 有现货 | 1,150.00 元 |
| IP5120 | 索莱宝 | ≥98% | 10mg | 有现货 | 4,190.00 元 |
| IP5120 | 索莱宝 | ≥98% | 5mg | 有现货 | 2,890.00 元 |
| 标准名称: | (S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-d]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺 | 英文名称： | PF-AKT400 |
|---|---|---|---|
| CAS： | 1004990-28-6 | 分子式： | C20H22F2N6O |
| 分子量： | 400.425090312958 | 颜色与性状： | |
| 密度： | 1.353 | 沸点： | |
| 熔点： | 水溶性： |
| CAS | 1004990-28-6 |
| 英文名称 | PF-AKT400 |
| 别名 | AKTproteinkinaseinhibitor2-Acetamido-5-Nitrothiazole;N-(5-Nitrothiazol-2-yl)acetamide |
| 分子式 | C20H22F2N6O |
| 分子量 | 400.43 |
| 规格 | 10mg ; 5mg ; 1mg |
| 溶解性 | Soluble in DMSO ≥5mg/mL |
| 纯度 | ≥98% |
| 外观(性状) | Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| 运输条件 | 冷藏运输 |
| SMILES | CCC1=CNC2=C1C(=NC=N2)N3CC[C@@](C3)(CNC(=O)C4=C(C=C(C=C4)F)F)N |
| InChIKey | MOZRQQTUYAYCQT-FQEVSTJZSA-N |
| InChI | InChI=1S/C20H22F2N6O/c1-2-12-8-24-17-16(12)18(27-11-26-17)28-6-5-20(23，10-28)9-25-19(29)14-4-3-13(21)7-15(14)22/h3-4，7-8，11H，2，5-6，9-10，23H2，1H3，(H，25，29)(H，24，26，27)/t20-/m0/s1 |
| PubChem CID | 25061501 |
| 靶点 | Akt |
| 通路 | PI3K/Akt/mTOR |
| 背景说明 | PF-AKT400 是一种有效的, ATP 竞争性的选择性 Akt 抑制剂。 |
| 生物活性 | PF-AKT400 is a broadly selective， potent， ATP-competitive Akt inhibitor， displays 900-fold greater selectivity for PKBα (IC50=0.5 nM) than PKA (IC50=450 nM).[1-2] |
| IC50 | PKBα:0.5nM;PKA:450nM[1] |
| In Vitro | PF-AKT400(Compound 42)provides significantly enhanced selectivity for Akt relative to earlier leads such as spiroindoline 2. Free IC50 and EC50 values are estimated for phospho-S6 reduction(110 nM)and Akt hyperphosphorylation(216 nM)，respectively. These values corresponded well to the cellular IC50 for PF-AKT400 in U87 cells measuring p-GSK-3α(310 nM)[2]. |
| In Vivo | PF-AKT400 is subsequently evaluated for modulation of Akt in tumors and in multiple in vivo mouse models of antitumor efficacy. It is active in a PC3 prostate carcinoma xenograft experiment，with 75% TGI observed at 100 mg/kg b.i.d. dosing for 10 days. In a colorectal carcinoma(Colo205)xenograft study，PF-AKT400 produces 60% TGI at 150 mg/kg b.i.d. after 10 days. Most intriguingly，in combination with Rapamycin(10 mg/kg，ip)，75 mg/kg b.i.d.(10 days)of PF-AKT400 results in 98% TGI in an additional PC3 prostate carcinoma xenograft study compared to 56% TGI and 66% TGI with PF-AKT400 and Rapamycin as single agents. To define the in vivo potency of PF-AKT400(Compound 42)in the PC3 xenograft model，oral administration of 25，75，and 100 mg/kg PF-AKT400 is performed with blood and tumor sampling over time. Immunoblot analysis of detergent-soluble extracts derived from PC3 tumors shows a significant reduction of S6 phosphorylation，and hyperphosphorylation of Akt upon treatment at doses that produced significant tumor growth inhibition. Plasma drug concentrations peak rapidly after oral administration of doses between 25-100 mg/kg(Tmax=0.5 h). Peak PD responses of phospho-S6 and phospho-Akt are observed at approximately 2-4h and 1h post-administration of PF-AKT400，respectively. The time-course of PD marker response is well described by a PK/PD model at doses that ranged from no efficacy(25 mg/kg)to maximal efficacy(100 mg/kg)[2]. |
| 动物实验 | Studies to describe the PK/PD relationship for PF-AKT400 are performed in male SCID/Beige mice bearing subcutaneous PC3 prostate carcinoma xenografts. Once tumors reach about ~300mm3 in size，PF-AKT400 is formulated in 0.5% methylcellulose vehicle and administered orally to 3 mice per dose group. Plasma and tumors are harvested over time，tumor lysates prepared，and the levels of phospho S6 reduction and phospho Akt induction are evaluated by immunoblot.[1] |
| 激酶实验 | A fluorescence polarization IMAP type assay is used. An amount of 15 μL of diluted PF-AKT400(Compound 42)in DMSO is mixed with 60 μL of reaction buffer(10 mM Tris-HCl，pH 7.5，10 mM MgCl2，0.1 mM EGTA，0.01% Triton-X100，1 mM DTT). Then 5 μL of the compound/buffer mixture，10 μL of a solution containing 4 μM ATP and 40 nM fluorescent-labeled Crosstide(Tamara-labeled GRPRTSSFAEG peptide)，and 5 μL of Akt1 protein(lacking the pleckstrin homology(PH)domain，containing an Asp at position 473，and prephosphorylated at Thr 308)in reaction buffer are combined. After a 90 min incubation，IMAP beads are added and plates are read(lamp filter，544 nm; emission filter，615 nm). The same procedure can be applied to full length Akt1 to provide similar results. All IC50 values are the geometric mean of at least n=2 determinations[2]. |
| 数据来源文献 | [1]. Chen SF， et al. Binding selectivity studies of PKBα using molecular dynamics simulation and free energy calculations. J Mol Model. 2013 Nov;19(11):5097-5112. [2]. Freeman-Cook KD， et al. Design of selective， ATP-competitive inhibitors of Akt. J Med Chem. 2010 Jun 24;53(12):4615-4622. |
| 单位 | 瓶 |
| 1mM-5mg | 12.4866mL |
| 1mM-1mg | 2.4973mL |
| 1mM-10mg | 24.9732mL |
| 5mM-1mg | 0.4995mL |
| 5mM-5mg | 2.4973mL |
| 5mM-10mg | 4.9946mL |
| 10mM-1mg | 0.2497mL |
| 10mM-5mg | 1.2487mL |
| 10mM-10mg | 2.4973mL |
公司拥有一批专业的研发人员，我们专注于生物产品的不断完善和创新。产品覆盖面广，品质可靠。先后开发了涵盖分子生物学、细胞生物学、免疫学、生物医学等领域的多种试剂及试剂盒。同时，索莱宝公司提供各种常规生化试剂，库存常备产品多达10000多种，可随时为广大科研工作者提供各类专业试剂。在质量方面，索莱宝谨记公司信念：质量高于一切。所有研发的产品都设有严谨的生产流程，科学的质量检测方法和成熟的质量检测程序，我们恪守对每一位用户的承诺：用专业的态度做专业的品牌。同时，公司组建了一支专业的技术服务队伍，能够为科研工作者提供专业的技术服务。每一位购买索莱宝产品的用户都能够得到专业的咨询和完善的售后服务。
索莱宝公司坚持与国际接轨，注重和国际先进企业的合作与交流，并提供产品代理、市场咨询等多项服务。公司将一如既往与世界更多知名品牌合作，不断为广大生物科研工作者提供更优质的产品和服务。公司理念：“为科研服务，为生命尽责”。一个人能够走多远，取决于与谁同行。索莱宝公司期待与各同行精诚合作。
索莱宝诚招生物试剂研发人员，期待与广大同行精诚合作，为广大科研工作者提供优质的产品，高效的物流以及专业的售后服务。索莱宝感谢所有朋友的支持与帮助，您的支持是我们前进的动力和保障。让我们携手同行，共同创造美好的明天。
| 企业认证： | 已认证 | 企业性质： | 生产研发 |
|---|---|---|---|
| 主营产品： | Peptide R9 ； Hexaarginine ； Tetraarginine ； Abaecin ； Neuropeptide Y (3-36) (porcine) ； | 供货范围： | 试剂 |
| 产品目录： | 119901 | 品牌： | 索莱宝 |
| 纯度 | 品牌 | 规格 | 发货地 |
|---|---|---|---|
| ≥95.0% | 索莱宝 | 10mg / 1mg / 5mg | 北京 |
| 纯度 | 品牌 | 规格 | 发货地 |
|---|---|---|---|
| ≥95.0% | 索莱宝 | 10mg / 1mg / 5mg | 北京 |
